A new journal where molecular biology meets clinical research

The European Molecular Biology Organization (EMBO) has announced the introduction of EMBO Molecular Medicine, a new journal dedicated to a research discipline focused on the interface between molecular biology and clinical research. The new journal, launching in 2009, will publish original research offering molecular insights into cellular and systemic processes underlying defined human diseases as well as potential clinical applications for diagnosis, prevention and therapy.

In line with EMBO's reputation for promoting the very best in the molecular life sciences, a renowned group of senior editors and an equally well respected advisory board assure published articles of the highest scientific quality following rapid, transparent and rigorous peer review.

"EMBO Molecular Medicine offers a unique opportunity to broadly distribute new findings in biomedical research and to strengthen links between clinicians and molecular biologists," said Hermann Bujard, EMBO Director. "We hope that published papers will lead to advances that will improve the detection, diagnosis and clinical management of diseases."

Articles will appear online and in print. In addition to research articles, the journal will publish review articles and editorials with innovative formats targeting a broad and unspecialised audience. A new format of review article, called Bridging the Gap, will aim to help molecular biologists and clinical researchers to understand each other's perspectives and to define common goals.

Submissions are invited from research groups at universities, independent research laboratories and pharmaceutical and biotechnology companies worldwide. EMBO Molecular Medicine offers free access to all content for the first two years of publication.

EMBO Molecular Medicine is published for EMBO by Wiley-Blackwell (the scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, Inc.) and joins the EMBO family of leading peer-reviewed journals - The EMBO Journal, EMBO reports and Molecular Systems Biology - that span a broad spectrum of topics of molecular biology and reflect how science is shaping the world.

For further information, please visit:
http://www.nature.com/emboj/index.html

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...